MA29366B1 - Therapie antiangiogenique de maladie auto-immune chez des patients qui n'ont pas reagi a une therapie anterieure - Google Patents

Therapie antiangiogenique de maladie auto-immune chez des patients qui n'ont pas reagi a une therapie anterieure

Info

Publication number
MA29366B1
MA29366B1 MA30069A MA30069A MA29366B1 MA 29366 B1 MA29366 B1 MA 29366B1 MA 30069 A MA30069 A MA 30069A MA 30069 A MA30069 A MA 30069A MA 29366 B1 MA29366 B1 MA 29366B1
Authority
MA
Morocco
Prior art keywords
therapy
reacted
autoimmune disease
anterior
patients
Prior art date
Application number
MA30069A
Other languages
English (en)
Inventor
Sunil Agarwal
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA29366B1 publication Critical patent/MA29366B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION CONCERNE UNE THÉRAPIE FAISANT APPEL À DES ANTAGONISTES ANGIOGÉNIQUES, PAR EXEMPLE DES ANTICORPS ANTI-VEGF. PLUS PRÉCISÉMENT, L'INVENTION CONCERNE L'UTILISATION DE CES ANTAGONISTES POUR TRAITER UNE MALADIE AUTO-IMMUNE CHEZ UN PATIENT QUI N'A PAS RÉAGI UN TRAITEMENT ANTÉRIEUR, PAR EXEMPLE UN TRAITEMENT FAISANT APPEL À DES DMARD OU À DES INHIBITEURS DE TNF$G(A).
MA30069A 2004-12-17 2007-07-12 Therapie antiangiogenique de maladie auto-immune chez des patients qui n'ont pas reagi a une therapie anterieure MA29366B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63716904P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
MA29366B1 true MA29366B1 (fr) 2008-04-01

Family

ID=36177836

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30069A MA29366B1 (fr) 2004-12-17 2007-07-12 Therapie antiangiogenique de maladie auto-immune chez des patients qui n'ont pas reagi a une therapie anterieure

Country Status (23)

Country Link
US (2) US20060134111A1 (fr)
EP (1) EP1824885A1 (fr)
JP (1) JP2008524241A (fr)
KR (1) KR20070086218A (fr)
CN (1) CN101120020A (fr)
AR (1) AR052056A1 (fr)
AU (1) AU2005316403A1 (fr)
BR (1) BRPI0518105A (fr)
CA (1) CA2587932A1 (fr)
CR (1) CR9181A (fr)
IL (1) IL183347A0 (fr)
MA (1) MA29366B1 (fr)
MX (1) MX2007007165A (fr)
NO (1) NO20073651L (fr)
NZ (1) NZ555286A (fr)
PE (1) PE20061075A1 (fr)
RU (1) RU2007126970A (fr)
SG (1) SG158089A1 (fr)
SV (1) SV2006002342A (fr)
TN (1) TNSN07191A1 (fr)
TW (1) TW200634026A (fr)
WO (1) WO2006066086A1 (fr)
ZA (1) ZA200704898B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1642596A3 (fr) * 1999-05-07 2006-04-12 Genentech, Inc. Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes B
KR20040023565A (ko) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
SI2380911T1 (en) 2003-11-05 2018-07-31 Roche Glycart Ag ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION
WO2006031689A2 (fr) 2004-09-13 2006-03-23 Genzyme Corporation Complexes multimeriques
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008031835A2 (fr) * 2006-09-13 2008-03-20 Novartis Ag Méthode de traitement de maladies auto-immunes à l'aide d'inhibiteurs de la voie vegf
TWI580694B (zh) * 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
US9289475B2 (en) 2008-11-06 2016-03-22 The Johns Hopkins University Treatment of chronic inflammatory respiratory disorders
CN114835812A (zh) * 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
CN102265156B (zh) * 2008-12-23 2014-11-05 默克专利有限公司 用于具有抗血管发生活性的抑制剂的生物标志
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CN102933231B (zh) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途
PT2601214T (pt) 2010-08-06 2017-12-20 Genzyme Corp Composições de antagonistas de vegf e utilizações destes
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
AU2015241038A1 (en) * 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
EP3056216B1 (fr) * 2015-02-11 2017-02-01 Deutsches Krebsforschungszentrum Thérapie anticancéreuse avec un parvovirus combiné avec du bévacizumab
EA202091710A1 (ru) 2018-03-09 2021-02-16 Агенус Инк. Антитела против cd73 и способы их применения

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) * 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP1185559A2 (fr) * 1999-04-28 2002-03-13 Board Of Regents, The University Of Texas System Compositions et procedes de traitement du cancer par inhibition selective de vegf
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences

Also Published As

Publication number Publication date
AU2005316403A1 (en) 2006-06-22
BRPI0518105A (pt) 2008-11-04
NZ555286A (en) 2010-04-30
JP2008524241A (ja) 2008-07-10
NO20073651L (no) 2007-09-10
SV2006002342A (es) 2006-06-01
SG158089A1 (en) 2010-01-29
WO2006066086A1 (fr) 2006-06-22
IL183347A0 (en) 2007-09-20
CR9181A (es) 2008-07-31
US20080214789A1 (en) 2008-09-04
CN101120020A (zh) 2008-02-06
EP1824885A1 (fr) 2007-08-29
AR052056A1 (es) 2007-02-28
RU2007126970A (ru) 2009-01-27
ZA200704898B (en) 2009-03-25
PE20061075A1 (es) 2006-11-15
MX2007007165A (es) 2007-08-14
TW200634026A (en) 2006-10-01
TNSN07191A1 (en) 2008-11-21
US20060134111A1 (en) 2006-06-22
CA2587932A1 (fr) 2006-06-22
KR20070086218A (ko) 2007-08-27

Similar Documents

Publication Publication Date Title
MA29366B1 (fr) Therapie antiangiogenique de maladie auto-immune chez des patients qui n'ont pas reagi a une therapie anterieure
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
MA32300B1 (fr) Anticorps anti-facteur d humanises et utilisations de ceux-ci
MA31668B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
MA30252B1 (fr) Vaccin therapeutique
WO2001054681A8 (fr) Composition anti-stress
MA27838A1 (fr) Traitement d'une maladie auto-immune chez un patient presentant une reponse inadequate a un inhibiteur de tnf-alpha
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
TNSN00256A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires, et compositions les contenant
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
MA28011A1 (fr) Derives de piperazine et leur utilisation en tant qu'agents therapeutiques
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
MA27863A1 (fr) Forme posologique à libération prolongée d'anesthésiques pour le traitement de la douleur
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
BR9813524A (pt) Processos para tratamento de toxicidades associadas com a administração de um agente terapêutico a um mamìfero, para tratamento de toxicidades associadas com a exposição de um mamìfero à terapia de radiação, para tratamento de neuro- ou nefrodistúrbios em um humano, e, para tratamento de distúrbios e sintomas clìnicos associados com diabetes do tipo i ou do tipo ii em um humano
MA27854A1 (fr) Traitement au moyen d'anticorps anti-vegf
RS20050344A (en) Treatment for hemorrhagic shock
YU33203A (sh) Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti
HUP0400548A2 (hu) Belső szemnyomást csökkentő hatóanyag-kombinációk alkalmazása glaukoma kezelésére szolgáló gyógyszerkészítmények előállítására
DE69943107D1 (de) Behandlung von autoimmunerkrankungen
Lederer et al. Unusual glomerular lesion in a patient receiving long-term interferon alpha
MA57226B1 (fr) Méthodes de traitement d'une splénomégalie
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif